Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Rapezzi

Showing results (361-370 of 404) with videos related to

Pageof 41
Sort By:
Heart (British Cardiac Society)|February 10, 2021
Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathyGiovanni Vitale, Raffaello Ditaranto, Francesca Graziani, et al.
International Journal of Cardiology|September 9, 2023
Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosisCarlo Fumagalli, Mattia Zampieri, Alessia Argirò, et al.
The New England Journal of Medicine|August 28, 2018
Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyMathew S Maurer, Jeffrey H Schwartz, Balarama Gundapaneni, et al.
JACC. Cardiooncology|November 29, 2022
Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic ValueAlberto Cipriani, Laura De Michieli, Aldostefano Porcari, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 5, 2023
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY studyAlberto Aimo, Lucio Teresi, Vincenzo Castiglione, et al.
Giornale Italiano Di Cardiologia (2006)|March 24, 2020
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts]Maddalena Lettino, Alberto Zambon, Giuseppe Musumeci, et al.
BMC Family Practice|September 24, 2020
Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitionerMorie Gertz, David Adams, Yukio Ando, et al.
JACC. Cardiovascular Imaging|November 5, 2021
The Authors' ReplyFrancesco Bandera, Raffaele Martone, Liza Chacko, et al.
JACC. Cardiovascular Imaging|August 22, 2021
Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin AmyloidosisFrancesco Bandera, Raffaele Martone, Liza Chacko, et al.
European Heart Journal|April 7, 2021
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial DiseasesPablo Garcia-Pavia, Claudio Rapezzi, Yehuda Adler, et al.
Pageof 41

Showing results (361-370 of 404) with videos related to

Sort By:
Pageof 41
Heart (British Cardiac Society)|February 10, 2021
Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathyGiovanni Vitale, Raffaello Ditaranto, Francesca Graziani, et al.
International Journal of Cardiology|September 9, 2023
Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosisCarlo Fumagalli, Mattia Zampieri, Alessia Argirò, et al.
The New England Journal of Medicine|August 28, 2018
Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyMathew S Maurer, Jeffrey H Schwartz, Balarama Gundapaneni, et al.
JACC. Cardiooncology|November 29, 2022
Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic ValueAlberto Cipriani, Laura De Michieli, Aldostefano Porcari, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|September 5, 2023
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY studyAlberto Aimo, Lucio Teresi, Vincenzo Castiglione, et al.
Giornale Italiano Di Cardiologia (2006)|March 24, 2020
[Appropriateness criteria for the management of lipid-lowering therapy with alirocumab in high cardiovascular risk patients. The opinion of a multidisciplinary group of Italian experts]Maddalena Lettino, Alberto Zambon, Giuseppe Musumeci, et al.
BMC Family Practice|September 24, 2020
Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitionerMorie Gertz, David Adams, Yukio Ando, et al.
JACC. Cardiovascular Imaging|November 5, 2021
The Authors' ReplyFrancesco Bandera, Raffaele Martone, Liza Chacko, et al.
JACC. Cardiovascular Imaging|August 22, 2021
Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin AmyloidosisFrancesco Bandera, Raffaele Martone, Liza Chacko, et al.
European Heart Journal|April 7, 2021
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial DiseasesPablo Garcia-Pavia, Claudio Rapezzi, Yehuda Adler, et al.
Pageof 41